Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11

Jill M. Goldstein, Hilal Sengul, Kathleen A. Messemer, Marcos Fernández-Alfara, Jessica C. Garbern, Amy C. Kristl, Richard T. Lee, Amy J. Wagers

Blood (2019) 134 (20): 1712–1716.

https://doi.org/10.1182/blood.2019002066

Published: 2019

Includes: Supplemental data

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients

Paola Delbini, PhD, Viola Ghiandai, Maria Domenica Cappellini, MD, Lorena Duca, Isabella Nava, Elena Cassinerio, MD, Irene Motta, MD

Blood (2019) 134 (Supplement_1): 3592.

https://doi.org/10.1182/blood-2019-130032

Published: 2019

Journal Articles

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

Mathieu Meunier, Camille Knosp, Chloe Friedrich, Johanna Zannoni, Jean-Yves Cahn, MD PhD, Olivier Kosmider, PharmD, PhD, Michaela Fontenay, MD PhD, Sophie Park, MD PhD

Blood (2019) 134 (Supplement_1): 1705.

https://doi.org/10.1182/blood-2019-128407

Published: 2019

Journal Articles

GDF11 is not the target of luspatercept

Clara Camaschella

Blood (2019) 134 (6): 500–501.

https://doi.org/10.1182/blood.2019001983

Published: 2019

Journal Articles

Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia

Amaliris Guerra, Paraskevi Rea Oikonomidou, Sayantani Sinha, Jianbing Zhang, Vania Lo Presti, Callum R. Hamilton, Laura Breda, Carla Casu, Ping La, Ana C. Martins, Anoop K. Sendamarai, Mark Fleming, Stefano Rivella

Blood (2019) 134 (6): 568–572.

https://doi.org/10.1182/blood.2019001057

Published: 2019

Includes: Supplemental data

Journal Articles

Evidence for an Alternative Mechanism Suppressing Hepcidin during the Recovery from Hemorrhage-Induced Anemia

Ugo Sardo, MS, Prunelle Perrier, BS, Benjamin Billore, BS, Kevin Cormier, MS, Leon C. Kautz, PhD

Blood (2018) 132 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2018-99-118647

Published: 2018

Journal Articles

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

Manja Wobus, Anna Mies, Nandini Asokan, Uta Oelschlaegel, Susann Winter, Martina Rauner, PhD, Lorenz Hofbauer, Martin Bornhäuser, Uwe Platzbecker

Blood (2018) 132 (Supplement 1): 939.

https://doi.org/10.1182/blood-2018-99-114536

Published: 2018

Journal Articles

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Blood (2018) 132 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2018-99-111770

Published: 2018

Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD

Blood (2017) 130 (Supplement 1): 2982.

https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982

Published: 2017

Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 255.

https://doi.org/10.1182/blood.V130.Suppl_1.255.255

Published: 2017

Journal Articles

Reprogramming Cell-Signaling By Delivering the Catalytic Domain of Ptpgr Ameliorates Anemia of β-Thalassemia

Alessandro Mattè, PhD, Elisabetta Beneduce, Michela Mirenda, PhD, Roberta Russo, Achille Iolascon, MD PhD, Antonella Pantaleo, PhD, Francesco Turrini, MD PhD, Angela Siciliano, Enrica Federti, PhD, Serge Cedrick, Anne Janin, PhD, Christophe Leboeuf, Carlo Laudanna, MD, Lucia De Franceschi, MD

Blood (2017) 130 (Supplement 1): 2219.

https://doi.org/10.1182/blood.V130.Suppl_1.2219.2219

Published: 2017

Journal Articles

New Therapeutic Options: Alternates to Gene Therapy for Treating Hemoglobinopathies

Lucia De Franceschi, MD

Blood (2016) 128 (22): SCI-49.

https://doi.org/10.1182/blood.V128.22.SCI-49.SCI-49

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

Journal Articles

Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS

Paraskevi Rea Oikonomidou, MD, Ping La, PhD, Ritama Gupta, MSc, Vania Lo Presti, Carla Casu, PhD, Laura Breda, PhD, Deborah Watson, PhD, Rajasekhar NVS Suragani, PhD, Ravindra Kumar, PhD, Stefano Rivella, PhD

Blood (2016) 128 (22): 2439.

https://doi.org/10.1182/blood.V128.22.2439.2439

Published: 2016

Journal Articles

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 5551.

https://doi.org/10.1182/blood.V128.22.5551.5551

Published: 2016

Journal Articles

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Andrew J. Yee, MD, Jacob P. Laubach, MD, Ajay K. Nooka, MD MPH, Elizabeth K. O'Donnell, MD, Edie A. Weller, PhD, Nicole R. Couture, BSN, RN, Ellen E. Wallace, BA, Jill N. Burke, NP, Cynthia C. Harrington, NP, Marie Puccio-Pick, MS, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4241.

https://doi.org/10.1182/blood.V126.23.4241.4241

Published: 2015

Journal Articles

Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia

Pedro A. Martinez, PhD, Rajasekhar NVS Suragani, PhD, Manoj Bhasin, PhD, Robert Li, Robert Scott Pearsall, PhD, Ravindra Kumar, PhD

Blood (2015) 126 (23): 751.

https://doi.org/10.1182/blood.V126.23.751.751

Published: 2015

Journal Articles

GDF11 Increased in Patients with Myelodysplastic Syndrome

Yu Han, Huaquan Wang, MD, Zonghong Shao, MD

Blood (2015) 126 (23): 5224.

https://doi.org/10.1182/blood.V126.23.5224.5224

Published: 2015

Journal Articles

Chronic Iron Overload Damage the Erythropoiesis in MDS Mouse By Increasing GDF11 and ROS Levels

Xiaoli Cao, MD, Mingfeng Zhao, MDPhD, Deguan Li, PhD, Yi Xing, MD, Jie Chen, MD, Xiaoyuan He, MD

Blood (2015) 126 (23): 2144.

https://doi.org/10.1182/blood.V126.23.2144.2144

Published: 2015

NARROW

Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

GDF11 is not the target of luspatercept

Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia

Evidence for an Alternative Mechanism Suppressing Hepcidin during the Recovery from Hemorrhage-Induced Anemia

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Reprogramming Cell-Signaling By Delivering the Catalytic Domain of Ptpgr Ameliorates Anemia of β-Thalassemia

New Therapeutic Options: Alternates to Gene Therapy for Treating Hemoglobinopathies

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia

GDF11 Increased in Patients with Myelodysplastic Syndrome

Chronic Iron Overload Damage the Erythropoiesis in MDS Mouse By Increasing GDF11 and ROS Levels

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only